Disease modeling with human iPSCs has come a long way since it first began almost 10 years ago. Many of us can probably remember the time when just making an iPSC line from a patient with a recognized disease was a notable achievement. It didn’t take long, however, before expectations rose and we moved quickly past recapitulating relevant phenotypes to the situation today in which most studies aim to either teach us something substantial that we didn’t know before about a given disease or show a path to potential therapies (or, hopefully, both).